In recent years, numerous investigators have reported novel cellular fates of multipotent stem or progenitor cells. In this review, we discuss the unexpected observations that hematopoietic stem cells can contribute to the hepatocyte lineage in humans and in rodent models of liver disease and regeneration. A key unresolved issue regarding hepatic regeneration from hematopoietic stem cells is whether the mechanism occurs through transdetermination, cell fusion, or other processes. A better understanding of the various stem or progenitor cells of the hepatic lineage may facilitate cellular transplantation approaches for the correction of hepatic function in patients with end-stage liver disease. q
Introduction
Recently, numerous reports have suggested that multipotential cells of the bone marrow give rise to hepatocytes, neurons, or primitive mesenchymal cells (Pereira et al., 1995) , muscle (Ferrari et al., 1998) , or astrocytes (Kopen et al., 1999) . Moreover, bone marrow cells enriched for hematopoietic stem cells (HSC, based on the Hoechst dye exclusion side population) are proposed to differentiate to muscle, and side population cells with myogenic activity can reconstitute hematopoiesis in lethally-irradiated mice (Gussoni et al., 1999) . These experiments report an unexpected plasticity or transdetermination of multipotent stem cells (or their progeny) when located in ectopic environments. An alternative interpretation is that the transplanted cells are not transdetermined but can adopt the phenotype of other cell types after spontaneous fusion (see below). The stem cell transdetermination work is significant in that it challenges well-accepted models of progressive lineage restriction during development. In this review, we discuss recent reports of HSC to hepatocyte transdetermination and the therapeutic potential for cellular transplantation in liver disease.
Stem cells have been defined as clonogenic cells capable of both self-renewal and differentiation to lineage-restricted progenitors and/or functionally specialized mature cells (Till and McCulloch, 1961) . In hematopoiesis, for example, the HSC is a multipotent cell that self-renews and generates all oligolineage progenitors and differentiated progeny of the blood system. Stem cells may respond to local morphogenetic cues and differentiate to display appropriate histotypic morphologies and gene expression profiles. Many of our current models of pattern formation, cell fate restriction, and transdetermination can be traced to pioneering work on Drosophila and Caenorhabditis elegans. Hadorn used the term transdetermination to describe changes in the state of cultured Drosophila imaginal discs (Hadorn, 1965) . For example, cultured genital discs usually generate genital disc structures after implantation to larvae and subsequent metamorphosis. Occasionally, genital discs undergo transdeterminations to give rise to leg or antenna structures. Another early archetype for stem cell transdetermination is homeotic transformation. In Drosophila, the homeotic mutation Antennapedia results in a transformation of distal antennae to second leg in the adult fruit fly. The Antennapedia mutation was found to influence the precursor cells of the antenna to adopt the fate of leg cells, at the clonal level and prior to proliferation of the cell lineage, metamorphosis, and morphogenesis of the adult appendage (Postlethwait and Schneiderman, 1969) . While the cellular and genetic mechanisms of multipotent stem cell fate determination in vertebrates, and the possible alternate outcomes where transdetermination may be expressed, are largely unknown, novel insights to these processes may come from examination of factors involved in pattern formation and progressive lineage restriction during development (Austin et al., 1997; Korinek et al., 1998) .
The fetal liver functions simultaneously as both a hematopoietic and hepatic organ, although each cell lineage has been considered separate and distinct. However, recent reports have suggested a novel lineage relationship between HSCs and hepatocytes. Adult bone marrow was identified as a potential source of hepatic progenitor cells (oval cells) (Petersen et al., 1999) , and hepatocytes (Alison et al., 2000; Theise et al., 2000a,b; Mallet et al., 2002) . Moreover, in female patients of peripheral blood transplants from male donors, donor-derived hepatocytes were detected in liver biopsies (Korbling et al., 2002) . Three different multipotent stem cells have been identified in bone marrow; the HSC, the mesenchymal stem cell (Pittenger et al., 1999) , and the multipotent adult progenitor cells (Reyes et al., 2001; Jiang et al., 2002) . To identify the bone marrow cells responsible for hepatocyte lineage differentiation, Lagasse et al. (2000) used an inducible animal model of tyrosinemia type 1, a lethal hereditary liver disease (Grompe et al., 1995) . Bone marrow cells were injected into lethally irradiated FAH 2/2 mice and after hematopoietic engraftment, liver failure was induced. Several months after transplantation, the animals had restored liver biochemical functions, normal weights, and numerous donor-derived hepatocytes in their liver.
Transplantation of highly purified adult bone marrow HSC into this animal model resulted in donor-derived hematopoietic and hepatic engraftment from as few as 50 HSC. Assuming that 5-10% of systemically infused HSC home to the bone marrow (Smith et al., 1991; Uchida et al., 1997) , then only five HSC were likely to have engrafted in the bone marrow, reconstituted the hematopoietic system, and eventually differentiated into hepatocytes. In order for HSC residing in the bone marrow to become functional hepatocytes in the liver, the cells must transit from bone marrow to peripheral blood, circulate to the liver, adhere to endothelial cells, extravasate across the endothelial barrier, home to the liver parenchyma, and integrate within the hepatic lobules. Little is known of the systemic factors emanating from injured livers that may facilitate HSC mobilization or of the liver homing and adhesion properties of HSC in the context of recruitment to a hepatic fate.
Single donor-derived hepatocytes can be detected in the liver parenchyma as early as 7 weeks following bone marrow transplantation, and while the early appearance of donor-derived hepatocytes in the liver parenchyma is not dependant on liver damage, continued expansion of hepatocyte nodules occurs only in tyrosinemic mice (Wang et al., 2002) . Bone marrow engraftment by HSC is clearly a prerequisite for production of HSC-derived hepatocytes since donor-derived hepatocytes were undetectable without total body irradiation prior to transplantation. Neither increased irradiation doses nor transplantation of purified bone marrow HSC (KTLS phenotype) enhanced the level of donor hepatocytes. Direct injection of bone marrow or HSC into the liver did not generate donor hepatocyte repopulation (Wang et al., 2002) .
Transdetermination or fusion of stem cells
Many research groups are currently scrutinizing prior reports of stem cell transdetermination, to establish which experiments provide unequivocal evidence of unexpected differentiation outcomes. Clearly it is necessary that well characterized, unambiguous tissue-specific markers must be chosen and the functional capacity of the cells should be demonstrated. One line of inquiry by several groups is to evaluate if indeed the observed stem cell transdetermination occurred, or if known stem or progenitor cells present in the transplanted donor cell population were actually responsible for the differentiation event. Although technically challenging, clonal analyses should be carried out to demonstrate that clonally derived cells reconstitute both the normally expected cell lineage(s) and the newly described lineages in the ectopic location. This is a crucial point when evaluating non-hematopoietic cells for blood forming capacity since HSC can engraft and reconstitute lethally-irradiated animals at near clonal frequencies (Smith et al., 1991; Uchida et al., 1997; Lagasse et al., 2000) . HSC constitutively transit from bone marrow to blood (Wright et al., 2001) , and therefore are present in blood recovered with the organ to be assessed for hematopoietic potential. Recently, a reevaluation of muscle to blood differentiation concluded that itinerate HSC, and not muscle-derived side population cells with myogenic activity as previously reported (Gussoni et al., 1999) , are present in sorted muscle cell suspensions and efficiently confer hematopoietic engraftment (McKinney-Freeman et al., 2002) .
Findings of stem cell transdetermination have come under even more intense examination with recent reports demonstrating that adult cells can adopt the phenotype of other cell types after spontaneously fusing with ES cells (Terada et al., 2002; Ying et al., 2002 ). An important future goal of stem cell research is to clearly distinguish possible stem cell transdetermination from fusion events. Importantly, however, to date there is no data demonstrating that a prospectively isolated, uncultured adult stem cell (such as HSCs defined by the KTLS phenotype) has a capacity to both fuse with other cells in vivo after transplantation and to subsequently differentiate into a cell type other than of hematopoietic origin. Even if fusion could occur in vivo, many such events could produce aberrant cells since not all fusion events are likely to result in cells that differentiate with normal histotypic appearance, gene expression profiles, or responses to normal physiological cues or homeostatic mechanisms following tissue damage. In the example of HSC-derived hepatocytes in the tyrosinemic FAH 2/2 mouse model, cells arising from a fusion event(s) must integrate to hepatic parenchyma with a normal histological appearance, restore normal physiological levels of serum transaminases, billirubin, and amino acids, proliferate extensively to repopulate 30-50% of the liver mass, and rescue the mouse from lethal liver failure (Lagasse et al., 2000) .
When purified HSCs generated hepatocytes in tyrosinemic FAH 2/2 mice, the donor cells were from C57Bl males and engrafted into 129SvJ females. Donor HSC-derived hepatocytes were distinguished from host cells by betagalactosidase and FAH expression and Y chromosome-FISH (donor cells are beta-galactosidase 1 , FAH 1 , Y chromosome 1 ). If HSC-derived hepatocytes were generated from cell fusion rather than stem cell transdetermination, such cells would initially be tetraploid would have a sex chromosome complement of XXXY. Tetraploid hepatocytes derived from HSC transdetermination would be XYXY. Clearly, X and Y chromosome-FISH could rapidly determine whether fusion was causative in the formation of hepatocytes from HSC. These experiments are currently in progress. Moreover, the strain origin of chromosomes 8 and 14 in any hepatocyte, regardless of DNA ploidy, could be determined by cytogenetic analysis of polymorphisms in centromeric heterochromatin (Akeson and Davisson, 1996) . Alternatively, single cell DNA PCR (Austin et al., 2001 ) to amplify polymorphic microsatellite sequences could determine if 129SvJ sequences are found in donorderived hepatocytes.
Stem cell transdetermination or fusion as a natural developmental/homeostatic process
The process of HSC differentiation into hepatocytes could be direct, or hierarchical as is commonly depicted for HSC differentiation to multiple blood lineages. In a hierarchical system, progenitors may exist that are committed to differentiate along the hepatocyte lineage yet do not exhibit a fully mature hepatocyte phenotype. An important unresolved issue is whether HSC-derived hepatic progenitor cells exist and if so are they present in bone marrow, blood, or liver. Such cells may share characteristics of HSC and hepatocytes. Recently, evidence has been presented for bone marrow progenitors that express hepatic markers and upon transplantation to the liver differentiate to hepatocyte-like cells (Avital et al., 2001) . Several cell sources from within the liver may contribute to the hepatic lineage following liver damage including hepatocytes, oval cells, and small hepatocyte-like progenitor cells (SHPCs). Are HSC-derived cells equivalent to the other hepatic progenitors?
Oval cells are small, heterogeneous liver cells with oval nuclei appearing after hepatic injury when hepatocyte proliferation is suppressed. The finding that some oval cells express antigens normally present on hepatic (for example alpha-fetoprotein or albumin) or biliary (cytokeratin 19, gamma-glutamyl transpeptidase, OV-6) cells, together with in vivo lineage marking studies support a role for oval cells as a precursor to mature hepatocytes (reviewed in Grisham and Thorgeirsson, 1997; Sell and Ilic, 1997) . Bone marrow was reported to serve as a potential source of hepatic oval cells induced in a rat hepatic injury model (Petersen et al., 1999) . Oval cells can express several markers found on bone marrow HSC (Thy-1, CD34, c-kit, and flk-2; Petersen et al., 1998) , and may represent intermediates in a bone marrow to hepatocyte lineage (Sell, 2001) .
Small hepatocyte-like progenitor cells are described as a novel cell population, antigenically distinct from oval cells and mature hepatocytes, mediating restitutive liver regeneration following partial hepatectomy when proliferation of mature hepatocytes and ovals cells is inhibited by retrorsine (Gordon et al., 2000a,b) . Regenerating nodules of SHPCs in the liver parenchyma were noted to exhibit marked similarities to regenerating hepatocytes in tyrosinemic FAH 2/2 mice or the urokinase-type plasminogen activator transgenic model . Analysis of the antigenic phenotype of HSC-derived hepatocytes may clarify their relationship to oval cells, SHPCs, or ductal bipotent hepatic progenitors. Similarly, transcriptome or proteome profiling of regenerated adult liver hepatocytes and HSC-derived hepatocytes could identify if there quantitative differences in gene expression between the two populations.
Cellular transplantation for clinical treatment of liver disease
Transplantation of hepatocytes or hepatic progenitors has gained acceptance recently as an approach for patients with end-stage liver failure, for whom orthotopic liver transplantation is the only available therapy. However, the availability of donor organs is limited and many of these patients die each year waiting for liver transplants. In many diseases requiring liver transplantation, correction of hepatocyte functional deficiency is a prime goal of the procedure. In these indications, hepatocyte transplantation, or gene transfer to resident hepatocytes, could serve to bridge patients to whole organ transplantation, provide metabolic support during liver failure, or replace whole organ transplantation in certain metabolic liver diseases (Strom et al., 1999) . Long-term survival and function of transplanted hepatocytes in the liver has been accomplished in rodent models Ponder et al., 1991) . Infusion of hepatocytes through the portal vein a patient with Crigler-Najjar syndrome resulted in persistent reduction of serum bilirubin and increased bilirubin conjugates in the bile (Fox et al., 1998) . Widespread application of hepatocyte transplantation is also limited, however, by organ availability, viability of isolated hepatocytes after cryopreservation, and potential formation of hepatocyte aggregates during injection that can obstruct the liver sinusoids resulting in portal hypertension or lead to fatal emboli.
HSC may be advantageous for liver regeneration compared to hepatocytes since bone marrow can be obtained from living donors using a moderately invasive procedure, cord blood or mobilized HSC are other readily available sources of HSCs, and tissue banks of cord blood and bone marrow are established in many countries. Additionally, repopulation of both the hematopoietic and hepatic system from the same donor can induce a state of immunological tolerance in the transplant recipient that could reduce or eliminate lifelong immunosuppression for the prevention of allograft rejection. Potential drawbacks of HSC for hepatocyte differentiation include the long time period for hepatocyte appearance (weeks to months in the mouse model), the ablation of bone marrow required for bone marrow transplantation, the limited ability (and ethical dilemma) to induce further hepatocyte damage in end-stage liver disease patients to allow engraftment of exogenous hepatocytes, the limited extent that allogeneic bone marrow transplantation could be implemented without the exacerbation of liver failure by graft versus host disease, and the limited ability to expand HSC in vitro.
Other cells, such as hepatic progenitors, could potentially serve as alternative cell grafts for restoration of liver function in patients requiring liver transplantation. Clues to the identification, isolation, and reconstitution of hepatocytes from hepatic progenitors can be found in studies of liver regeneration. It is well established that in the regenerative process following partial hepatectomy, mature hepatocytes proliferate to restore liver cell mass and physiologic function (Michalopoulos and DeFrances, 1997) . Intriguingly, under certain pathophysiological conditions or following suppression of hepatocyte proliferation prior to hepatic injury, putative hepatic progenitor cells, such as oval cells, will proliferate and eventually differentiate into hepatocytes in the adult liver (Bisgaard and Thorgeirsson, 1996; Alison et al., 2001 ). Liver epithelial cell lines with stem cell-like properties have been characterized from normal rat livers and upon transplantation can incorporate into hepatic plates of recipient rats (Grisham et al., 1993) . Transplantation of fetal rat liver epithelial cells into adult rats can result in extensive reconstitution of donor-derived hepatocytes and bile duct cells, suggesting the presence of a bipotent hepatic progenitor, in contrast to adult hepatocytes that generate hepatocytes but not bile duct cells (Sandhu et al., 2001) . Clonogenic hepatic progenitors from rat and mouse fetal livers with bipotent features have been described that differentiate towards the hepatocyte lineage in vitro (Kubota and Reid, 2000; Suzuki et al., 2000) and prospective isolation of highly-enriched cells with in vivo hepatic progenitor activity has been accomplished from the mid-gestational mouse liver (Suzuki et al., 2000 (Suzuki et al., , 2002 . Similar studies describing a prospectively isolated, clonogenic human hepatic progenitor from the liver capable of hepatocyte lineage differentiation in vivo has not yet been reported. It is clear from the foregoing discussion that liver hepatocytes may arise from either extra-hepatic progenitors (HSC), or one of several intra-hepatic progenitors, or hepatocytes. The future development of hepatocytes or progenitors for cellular therapies of liver disease will require critical examination of safety, sustained engraftment, reconstitution of hepatocyte function, and potential for ex vivo expansion with maintenance of biopotency.
